Blueprint Medicines Corp

• Country

  United States of America

• Sector

  Health Care

• Industry group

  Pharmaceuticals, Biotechnology & Life Sciences

• Industry

  Biotechnology

• Sub-sector

  Health Care

• Capitalization (millions of $)

  5342.5

• Ticker

  BPMC.O

• ISIN

  US09627Y1091

• IPO date

  2015-04-30

• Availability on Russian exchanges

  Yes

• Reporting for

  2024-02-15

• Date fact. publication of reports

  2023-12-31

Blueprint Medicines Corporation is a precision therapy company focused on genomically defined cancers and hematologic disorders. The Company is focused on crafting drug candidates that provide clinical responses to patients without adequate treatment options. Its lead medicines are AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib). Avapritinib is used for the treatment of systemic mastocytosis (SM), a rare hematologic disorder that causes an overproduction of mast cells and the accumulation of mast cells in the bone marrow and other organs. It is also commercializing avapritinib for the treatment of patients with PDGFRA exon 18 mutant gastrointestinal stromal tumors (GIST). The Company is developing and commercializing pralsetinib for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC), and for the treatment of RET-altered thyroid carcinoma, including medullary thyroid carcinoma (MTC).